What was the overall market valuation of the US hemoglobinopathies market in 2024?

The overall market valuation was $1579.2 Million in 2024. Read More

What is the projected market valuation for the US hemoglobinopathies market by 2035?

The projected valuation for 2035 is $2684.1 Million. Read More

What is the expected CAGR for the US hemoglobinopathies market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 4.94%. Read More

Which segment had the highest valuation in the treatment type category in 2024?

In 2024, the medication segment had the highest valuation at $600.0 Million to $950.0 Million. Read More

What are the key players in the US hemoglobinopathies market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Pfizer, Roche, Sanofi, Vertex Pharmaceuticals, Hemogenyx Pharmaceuticals, and Bluebird Bio. Read More

Which diagnosis type segment had the highest valuation in 2024?

The genetic testing segment had the highest valuation in 2024, ranging from $500.0 Million to $800.0 Million. Read More

What is the valuation range for the sickle cell disease segment in 2024?

The valuation range for the sickle cell disease segment in 2024 was $600.0 Million to $1000.0 Million. Read More

How does the valuation of hereditary persistence of fetal hemoglobin compare to other segments?

The hereditary persistence of fetal hemoglobin segment had a valuation range of $179.2 Million to $384.1 Million, which is lower than other segments. Read More

What is the projected growth trend for the US hemoglobinopathies market from 2024 to 2035?

The market is expected to grow from $1579.2 Million in 2024 to $2684.1 Million by 2035. Read More

Which end user segment had the highest valuation in 2024?

In 2024, the hospitals segment had the highest valuation, ranging from $631.68 Million to $1085.23 Million. Read More

US Hemoglobinopathies Market

ID: MRFR/HC/18118-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Hemoglobinopathies Market Research Report: Size, Share, Trend Analysis By Types (Sickle Cell Disease, Thalassemia, Hemoglobin C Disease, Drew's Syndrome), By Diagnosis (Blood Tests, Genetic Testing, Newborn Screening), By Treatment (Blood Transfusion, Bone Marrow Transplant, Medication, Gene Therapy) and By End Users (Hospitals, Clinics, Homecare) - Growth Outlook & Industry Forecast 2025 To 2035

US Hemoglobinopathies Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)4.94%

2024 Market Size$ 1,579.2 Million

2025 Market Size$ 1,657.21 Million

2035 Market Size$ 2,684.1 Million

Key Players

Novartis

Bristol-Myers Squibb

Amgen

Pfizer

Roche

Sanofi

Trends

Rising Awareness and Education
Advancements in Gene Therapy
Integration of Telehealth Services

Opportunities

Government Initiatives and Funding
Rising Demand for Targeted Therapies
Advancements in Diagnostic Technologies

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Type (USD Million)
  1. 4.1.1 Sickle Cell Disease
  2. 4.1.2 Thalassemia
  3. 4.1.3 Hemoglobin E Disease
  4. 4.1.4 Hereditary Persistence of Fetal Hemoglobin
2. 4.2 Security, Access Control and Robotics, BY Diagnosis Type (USD Million)
  1. 4.2.1 Blood Tests
  2. 4.2.2 Hemoglobin Electrophoresis
  3. 4.2.3 Genetic Testing
  4. 4.2.4 Complete Blood Count
3. 4.3 Security, Access Control and Robotics, BY Treatment Type (USD Million)
  1. 4.3.1 Blood Transfusion
  2. 4.3.2 Bone Marrow Transplant
  3. 4.3.3 Medication
  4. 4.3.4 Gene Therapy
4. 4.4 Security, Access Control and Robotics, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Diagnostic Laboratories
  3. 4.4.3 Research Institutions
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Roche (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Vertex Pharmaceuticals (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Hemogenyx Pharmaceuticals (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bluebird Bio (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS TYPE
4. 6.4 US MARKET ANALYSIS BY TREATMENT TYPE
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 (% SHARE)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS TYPE, 2024 (% SHARE)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT TYPE, 2024 (% SHARE)
17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Type (USD Million, 2025-2035)

Sickle Cell Disease
Thalassemia
Hemoglobin E Disease
Hereditary Persistence of Fetal Hemoglobin

Security, Access Control and Robotics By Diagnosis Type (USD Million, 2025-2035)

Blood Tests
Hemoglobin Electrophoresis
Genetic Testing
Complete Blood Count

Security, Access Control and Robotics By Treatment Type (USD Million, 2025-2035)

Blood Transfusion
Bone Marrow Transplant
Medication
Gene Therapy

Security, Access Control and Robotics By End User (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Research Institutions

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”